Neurocrine Biosciences (NBIX) Releases Earnings Results, Beats Expectations By $0.07 EPS

Neurocrine Biosciences (NBIX) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $-0.22 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $-0.29. The company posted revenue of $15.00 million in the period, compared to analysts expectations of $15.43 million. The company’s revenue was down -24.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.01 EPS.

Neurocrine Biosciences closed down -2.14 points or -4.75% at $42.91 with 9,61,222 shares getting traded on Wednesday. Post opening the session at $44.7, the shares hit an intraday low of $42.67 and an intraday high of $45 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 13, 2016, Kyle Gano (Chief Business Development Off) sold 41,770 shares at $43.77 per share price. According to the SEC, on Apr 8, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 25,000 shares at $45.00 per share price. On Feb 4, 2016, Dimitri E. Grigoriadis (Chief Research Officer) sold 1,375 shares at $37.98 per share price, according to the Form-4 filing with the securities and exchange commission.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Neurocrine Biosciences

Leave a Reply

Neurocrine Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neurocrine Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.